To Get Full Access :

Paxlovid

Paxlovid is an oral treatment for mild to moderate COVID-19 in high-risk patients. It stops the virus from multiplying and helps prevent severe illness when taken early.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Nirmatrelvir And Ritonavir
  • Innovator :

    PFIZER INC
  • Approval Date :

    25-May-23
  • NCE-1 Date :

    25-May-27
  • NCE Date :

    25-May-28
  • Dosage Form :

    Tablet
  • Strength :

    150MG; 100MG; 300MG; 100MG
  • Therapeutic Category :

    Antiviral
  • Revenue ($M) :

    5,716

Year-wise Projected Sales ($M) :

  • 2025 :

    3,916
  • 2026 :

    3,800
  • 2027 :

    3,675
  • 2028 :

    3,526
  • 2029 :

    3,401
  • 2030 :

    3,277
  • 2031 :

    3,147
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?